INTRANASAL CRH CHALLENGE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 促肾上腺皮质激素释放激素存在于身体和大脑中。它是一种压力荷尔蒙，会在压力事件后释放出来。我们认为，它可能在抑郁症等疾病中发挥作用，因此可能值得研究，以开发未来抑郁症和其他精神疾病的治疗方法。本研究中使用的促肾上腺皮质激素释放因子的形式为皮质可瑞林。皮质醇是在实验室中制造的，类似于绵羊体内的促肾上腺皮质激素释放因子。它被FDA批准用于测试脑下垂体和肾上腺在体内的工作情况，通常通过静脉注射或静脉给药。在这项研究中，我们不是用它来测试你的脑垂体或肾上腺，而是以鼻腔喷雾器的形式给药。因此，它在本研究性研究中的使用被认为是实验性的。我们预计你的身体在鼻腔内吸收的药物比静脉注射时要少得多。这应该会降低药物的风险。 20名健康志愿者和20名有抑郁症病史的非抑郁症受试者将在两个非连续的研究日接受双盲、安慰剂交叉挑战，并使用鼻内CRH。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Corticotropin releasing hormone is present in the body and brain. It is a stress hormone that is released in response to a stressful event. We think that it may play a role in disorders such as depression, and thus may be worth studying in order to develop future treatments of depression and other psychiatric disorders. The form of corticotropin releasing factor being used in this study is corticorelin. Corticorelin is made in a laboratory to be similar to the type of corticotropin releasing factor in sheep. It is FDA approved for testing how well the pituitary and adrenal glands work in the body, and is usually given through an intravenous line, or IV. In this study, we are not using it to test your pituitary or adrenal glands, and instead of giving it IV, we are giving in the form of a nasal sprayer. Therefore its use in this research study is considered experimental. We expect that the amount of drug your body absorbs intranasally to be much less than when the drug is given IV. This should decrease the risks of the drug. 20 healthy volunteers and 20 non-depressed subjects with a history of depression will undergo a double-blind, placebo-crossover challenge with intranasal CRH on two non-consecutive study days.